Business
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The findings further support KIO-104 as a promising therapeutic candidate for inflammatory and proliferative diseases of the retina that lead to vision threatening scarring. The presentat
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The findings further support KIO-104 as a promising therapeutic candidate for inflammatory and proliferative diseases of the retina that lead to vision threatening scarring. The presentation, titled, "KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model," was presented by Romana Seda-Zehetner, MSc MScTox, Kiora's Director, Preclinical Development at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.","length":846,"tagName":"p"},{"type":"text","content":""PVR is the leading complication following retinal detachment surgery," said Eric J. Daniels, M.D., Chief Development Officer for Kiora. "This condition is driven by uncontrolled cellular proliferation, fibrosis, and inflammation. This results in scarring which may lead to repeated retinal detachments as well as progressive and permanent loss of vision. Given the reduction in scar formation and scar size observed in this study and the fact that there are no approved drugs for this condition, further development of KIO-104 in PVR is warranted."","length":569,"tagName":"p"},{"type":"text","content":"The study evaluated the efficacy of intravitreal delivery at multiple dose levels of KIO-104, a small molecule, DHODH inhibitor, in the prevention of PVR-related scar formation. The study used an established retinal detachment model in rabbits that mimics the structural and functional disruption observed in human retinal detachment including glial reactivity, subretinal fibrosis, immune cell infiltration, and glial scar formation. By disrupting an essential molecular pathway for rapidly dividing cells, de novo biosynthesis of pyrimidine nucleotides, KIO-104 significantly reduced scar formation in a dose-dependent manner. Findings include the following:","length":660,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The high dose group (n=6) exhibited complete prevention of scar formation in all rabbits.","len...